Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Ginkgo Bioworks Holdings Inc

2 Biotech Stocks That Are Screaming “SELL ME!”

The biotech sector is witnessing the headwinds from the banking crisis, layoffs, and the Inflation Reduction Act. So, fundamentally weak biotech stocks Ginkgo Bioworks Holdings (DNA) and Novavax (NVAX) might be best avoided. Read on.

StockNews.com

4 Ultra-Popular Stocks You Should Sell Right Now

Following the strong labor market report, the Federal Reserve will likely keep the interest rate hikes going. Moreover, the increasing gap between 2 and 10-year treasury notes indicates a potential recession might be on the horizon. Hence it should be best to avoid ultra-popular stocks Ginkgo Bioworks (DNA), Affirm (AFRM),…

StockNews.com

3 F-Rated Stock to Stay Far Away From

With the Fed signaling to keep raising interest rates in 2023 and other unfavorable economic reports, recession odds are rising. Amid ongoing market uncertainties, it could be wise to stay away from fundamentally weak stocks Lucid (LCID), Ginkgo Bioworks (DNA), and Bed Bath & Beyond (BBBY), which are rated Strong…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

4 Stocks That Have Run out of Energy

Amid major macroeconomic headwinds, consumer confidence declined to its lowest since July. In addition, the bear market rally is likely to continue into next year. Hence, fundamentally weak stocks SoFi Technologies (SOFI), Ginkgo Bioworks (DNA), Opendoor Technologies (OPEN), and Camber Energy (CEI), which have been slumping in price, might be…

StockNews.com

2 Biotech Stocks to Buy in November and 1 to Sell

The biotech industry strengthened over the pandemic by drug and vaccine development initiatives to combat COVID-19. Moreover, significant government investments should bode well for this industry. Therefore, quality biotech stocks Amgen (AMGN) and Gilead Sciences (GILD) could be ideal buys in November. However, fundamentally weak stock Ginkgo Bioworks (DNA) might…

StockNews.com

3 F-Rated Stocks to Sell Now Rather Than Later

Although inflation is showing signs of cooling, it's still far from the Fed’s target, and the rate hikes shall continue. As the global economic outlook worsens, we believe fundamentally weak stocks Ginkgo Bioworks (DNA), Affirm Holdings (AFRM), and WeWork (WE), which are F-rated in our proprietary rating system, might be…

StockNews.com

2 Biotech Stocks to Take off Your Watchlist in 2022

Amid the macroeconomic issues and rampant volatility in the market, investor sentiment toward biotech stocks is declining. Many companies in this space are planning layoffs to reduce expenses. Amid the grim backdrop, we think investors should drop fundamentally weak biotech stocks Ginkgo Bioworks Holdings (DNA) and Immunic (IMUX) from their…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

4 Cathie Wood Stocks to Sell Now

Cathie Wood’s ETFs performed miserably this year amid a market rout caused by soaring inflation, the Fed’s aggressive rate hikes, and rising odds of a recession. More trouble awaits her hedge fund, concentrated in tech, as September job gains almost affirm another aggressive rate hike in the Fed’s next meeting.…

StockNews.com

5 Stocks to Delete From Your Watchlist in Q4

The stock market has been experiencing wild swings this year, with inflation at a multi-decade high and the Fed aggressively raising interest rates to bring it under control. Amid rising recession worries, we think fundamentally weak stocks, Advanced Micro Devices (AMD), Block (SQ), Ginkgo Bioworks (DNA), Rocket Lab USA (RKLB),…

StockNews.com

The Worst Biotech Stock to Own in September

Biotech stock Ginkgo Bioworks (DNA) has fallen more than 60% year-to-date. The company has been making some acquisitions recently to aid its growth over the next few years. However, given its weak financials and unfavorable analyst estimates, it may not be wise to invest in this stock now. Continue reading….

StockNews.com

Cathie Wood Doubled Down on This Biotech Stock, Should You?

Biotech company Ginkgo Bioworks’ (DNA) top-line growth didn’t translate into bottom-line improvement in its last quarter. The stock is currently trading approximately 84% below its 52-week high, and analysts expect the company to report significant losses in the fiscal 2022 and 2023. However, since renowned investor Cathie Wood has recently…

StockNews.com

3 Healthcare Stocks Wall Street Expects to Soar Nearly 200%

Substantial investments in R&D and growing demand for advanced drugs to treat chronic diseases should drive the healthcare industry’s growth. Moreover, amid the economy's uncertainties, the inelastic demand is expected to keep the sector resilient. Given this backdrop, Wall Street analysts expect healthcare stocks Ginkgo Bioworks (DNA), Zai Lab (ZLAB),…

StockNews.com

Why Ginkgo Bioworks Shares Are Rising After Announcement With Partner Cronos Group

Ginkgo Bioworks Holdings Inc (NYSE: DNA) shares are trading higher by 7.63% to $2.68 after the company, and Cronos Group Inc (NASDAQ: CRON), announced the achievement of the third target productivity milestone in their par

Benzinga

BofA Downgrades Ginkgo Bioworks, Cuts Price Target In Half

While Ginkgo Bioworks Holdings Inc’s (NYSE: DNA) overall first-quarter results were better than expected, revenues and active programs in its core Foundry segment fell short of estimates, according to BofA Securities.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Why Ginkgo Bioworks Stock Is Falling After Hours

Ginkgo Bioworks Holdings Inc (NYSE: DNA) shares are trading lower in Monday's after-hours session after the company

StockNews.com

5 Beaten-Down Biotech Stocks Cathie Wood Loves

Renowned investor Cathie Wood of ARK Invest is known for her eye for stocks with enormous upside potential. Despite recent macro headwinds, the biotech industry is expected to grow tremendously in 2022, supported by strong demand for healthcare and medical products and increasing investments in R&D. Given these factors, Wall…

Benzinga

Elanco, Ginkgo Bioworks Launch BiomEdit, Microbiome-Focused Animal Health Firm

Elanco Animal Health Incorporated (NYSE:ELAN) and Ginkgo Bioworks Holdings Inc (NYSE:DNA) have launched BiomEdit, a microbiome innovation company. BiomEdit will discover, develop and introduce novel probiotics, bioactive molecules, engineered microbial medicines, and microbial monitoring services for animal health. In October last year, Elanco announced its intention to carve out its microbiome platform and pipeline under the leadership…

StockNews.com

Is Ginkgo Bioworks a Buy Under $5?

Cell programming platform operator Ginkgo Bioworks (DNA) went public late last year in an SPAC merger. Since then, the stock has plummeted more than 60% in price, closing yesterday’s session at $4.13. In addition, analysts have increased their loss per share expectations for the stock for this year. So, would…

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Here's Why Ginkgo Bioworks Shares Are Rising

Ginkgo Bioworks Holdings Inc (NYSE: DNA) shares are trading higher by 22.0% at $4.56 after the company reported better-than-expected fourth-quarter sales results and issued FY22 sales guidance above analyst estimates.

Benzinga

Ginkgo Bioworks Shares Gain As Q4 Sales, FY22 Guidance Surpass Street Expectations

Ginkgo Bioworks Holdings Inc (NYSE: DNA) reported

Benzinga

Why Ginkgo Bioworks Stock Is Rising After Hours

Ginkgo Bioworks Holdings Inc (NYSE: DNA) is trading higher in Monday's after-hours session after the company reported financial results and issued guidance above estimates.

Benzinga

Ginkgo Bioworks Adds Ultra-High-Throughput Screening Platform Via FGen Acquisition

Ginkgo Bioworks Holdings Inc (NYSE: DNA) has

Benzinga

Why BofA Sees 'Better Entry Point' In Ginkgo Bioworks Stock

Ginkgo Bioworks Holdings Inc (NYSE: DNA) is “at the forefront of the rising SynBio wave, a market we think holds much long-term promise,” according to BofA Securities.

People

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

595 stories

de Bruin

12 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.